252 results on '"A, Masson-Lecomte"'
Search Results
2. Second TURB, restaging TURB or repeat TURB in primary T1 non-muscle invasive bladder cancer: impact on prognosis?
3. Survival after sequential neoadjuvant chemotherapy followed by trimodal treatment or radical cystectomy for muscle-invasive bladder cancer
4. Efficacy of hyperthermic intravesical chemotherapy (HIVEC) in patients with non-muscle invasive bladder cancer after BCG failure
5. Safety and efficacy of preoperative chemotherapy for muscle-invasive bladder cancer in elderly patients
6. Patients non répondeurs au BCG
7. Consistencies in Follow-up After Radical Cystectomy for Bladder Cancer: A Framework Based on Expert Practices Collaboratively Developed by the European Association of Urology Bladder Cancer Guideline Panels
8. Management of high-grade papillary Ta or T1 bladder cancer after restaging transurethral resection: A retrospective study comparing Bacillus Calmette–Guerin therapy upfront versus a third resection
9. Intraoperative complication of radical cystectomy for muscle-invasive bladder cancer: does the surgical approach matter? A retrospective multicenter study using the EAUiaiC classification
10. Salvage Percutaneous Cryoablation for Bleeding Upper Tract Urothelial Carcinoma
11. International Opinions on Grading of Urothelial Carcinoma: A Survey Among European Association of Urology and International Society of Urological Pathology Members
12. Principios generales de la cirugía asistida por robot
13. Profil et environnement immunitaires des tumeurs de la voie excrétrice supérieure
14. Transcriptomic Profiling of Upper Tract Urothelial Carcinoma: Bladder Cancer Consensus Classification Relevance, Molecular Heterogeneity, and Differential Immune Signatures
15. Bladder Recurrence Following Upper Tract Surgery for Urothelial Carcinoma: A Contemporary Review of Risk Factors and Management Strategies
16. Chimiothérapie préopératoire des tumeurs des voies excrétrices supérieures : impact sur la fonction rénale
17. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update
18. International Opinions on Grading of Urothelial Carcinoma: A Survey Among European Association of Urology and International Society of Urological Pathology Members
19. Inmunoterapia en urología: principios e indicaciones
20. Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non–muscle-invasive Spectrum
21. Bladder Recurrence Following Upper Tract Surgery for Urothelial Carcinoma: A Contemporary Review of Risk Factors and Management Strategies
22. Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration
23. T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non–muscle-invasive Bladder Cancer Spectrum
24. French AFU Cancer Committee Guidelines – Update 2022–2024: Upper urinary tract urothelial cancer (UTUC)
25. French AFU Cancer Committee Guidelines - Update 2022-2024: Non-muscle-invasive bladder cancer (NMIBC)
26. French AFU Cancer Committee Guidelines – Update 2022–2024: Muscle-Invasive Bladder Cancer (MIBC)
27. Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guérin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration
28. Perioperative results of radical cystectomy after neoadjuvant chemotherapy according to the implementation of ERAS pathway
29. Recommandations du Comité de cancérologie de l’Association Française d’Urologie (CC-AFU) pour la bonne pratique des instillations intravésicales de mitomycine C, d’épirubicine et de BCG pour le traitement des tumeurs de la vessie n’infiltrant pas le muscle (TVNIM)
30. Instauration du traitement adjuvant endovésical par épirubicine des tumeurs de vessie n’infiltrant pas le muscle : premier retour national d’expérience du CC-AFU vessie
31. Recommandations des Comités de cancérologie (CC-AFU) et d’infectiologie (CI-AFU) de l’Association française d’urologie pour la prise en charge effets indésirables et complications du BCG
32. Efficacy and tolerance of hyperthermic intravesical chemotherapy (HIVEC) according to the number of instillations administered.
33. Perioperative outcomes of transurethral resection for t1 bladder tumors: quality evaluation based on patient, tumor and surgeon criteria
34. PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment
35. Consistencies in follow-up after radical cystectomy for bladder cancer: A practice-based framework by collaborative EAU bladder cancer guideline panels
36. Individual patient data validation of the definitions of BCG failure in patients with non-muscle invasive urothelial carcinoma of the bladder: An international multi-centre retrospective study
37. Towards defining follow-up strategies for patients with primary (first diagnosis) EAU2021 intermediate-risk non-muscle invasive bladder cancer
38. Methods for Establishing a Renal Cell Carcinoma Tumor Spheroid Model With Immune Infiltration for Immunotherapeutic Studies
39. Oncological outcomes of chemohyperthermia with HIVEC for BCG-unresponsive non-muscle invasive bladder cancer : results from a multicenter national database
40. Inmunoterapia en urología: principios e indicaciones
41. Intraoperative complication of radical cystectomy for muscle-invasive bladder cancer: does the surgical approach matter? A retrospective multicenter study using the EAUiaiC classification
42. A prospective descriptive 1‐year study in France of all <scp>BCG</scp> therapy dispensations for <scp>non‐muscle‐invasive bladder cancer</scp>
43. Salvage Percutaneous Cryoablation for Bleeding Upper Tract Urothelial Carcinoma
44. French AFU Cancer Committee Guidelines – Update 2022–2024: Upper urinary tract urothelial cancer (UTUC)
45. French AFU Cancer Committee Guidelines – Update 2022–2024: Muscle-Invasive Bladder Cancer (MIBC)
46. French AFU Cancer Committee Guidelines - Update 2022-2024: Non-muscle-invasive bladder cancer (NMIBC)
47. Do current definitions of BCG failure/ BCG unresponsive NMIBCs correlate with disease progression? Results of an individual patient data validation international multi-center retrospective study
48. Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non-muscle-invasive Spectrum
49. Prognosis of primary papillary Ta-G3 bladder cancer in the non-muscle invasive spectrum
50. Perioperative results of radical cystectomy after neoadjuvant chemotherapy according to the implementation of ERAS pathway
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.